# 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

> **NCT04868604** · PHASE1,PHASE2 · RECRUITING · sponsor: **Clarity Pharmaceuticals Ltd** · enrollment: 54 (estimated)

## Conditions studied

- Prostatic Neoplasms, Castration-Resistant

## Interventions

- **DRUG:** 64Cu-SAR-bisPSMA
- **DRUG:** 67Cu-SAR-bisPSMA

## Key facts

- **NCT ID:** NCT04868604
- **Lead sponsor:** Clarity Pharmaceuticals Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-11
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04868604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04868604, "64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04868604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*